Portal hypertension remains a cardinal pathophysiological hallmark of cirrhosis, mediating its most severe complications, most notably ascites and variceal hemorrhage. Accordingly, it represents a critical therapeutic target to prevent the life-threatening sequelae associated with advanced liver disease. A substantial body of evidence has consistently demonstrated that effective reduction in portal pressure markedly diminishes the risk of hepatic decompensation and correlates with improved overall survival in this patient population.
Since the 1980s, nonselective beta-blockers (NSBBs) have emerged as cornerstone pharmacologic agents in the management of portal hypertension. Their therapeutic efficacy stems from dual mechanisms: β1-adrenergic blockade, which decreases cardiac output, and β2-adrenergic blockade, which reduces splanchnic blood flow. Propranolol was the first NSBB used for this indication; however, subsequent investigations underscored the potential advantages of carvedilol, attributed to its additional α1-adrenergic antagonistic properties that promote intrahepatic vasodilation and further enhance portal pressure reduction. Notably, Frishman et al1 reported that carvedilol exhibited approximately fourfold greater potency compared to propranolol in clinical trials evaluating efficacy in heart failure, suggesting a potential therapeutic superiority in the management of portal hypertension.
Research efforts have been dedicated to comparing the efficacy of various NSBBs, with the overarching aim of identifying the agent most effective in reducing risk of variceal hemorrhage and optimizing clinical outcomes. Prior comparative studies predominantly emphasized bleeding-related endpoints, with limited attention to broader clinical outcomes, including hepatic decompensation and mortality. In this context, the landmark PREDESCI trial2 provided pivotal insights, demonstrating that NSBB therapy not only reduces the incidence of variceal bleeding in patients with high-risk varices but also significantly lowers the risk of hepatic decompensation and mortality among patients with compensated cirrhosis and clinically significant portal hypertension (CSPH). This paradigm-shifting trial fundamentally redefined the therapeutic role of NSBBs in the management of cirrhosis, although it did not establish a definitive preference between carvedilol and propranolol.
Building on this foundation, the recent study, “Carvedilol Is Associated with Lower Mortality than Other Nonselective Beta-Blockers in Patients with Cirrhosis,”3 sought to further elucidate the comparative efficacy of NSBBs. Specifically, the authors compared clinical outcomes among patients treated with carvedilol versus propranolol or nadolol, focusing on a population with CSPH and incorporating additional clinically practical surrogates to enhance real-world applicability. As anticipated, given carvedilol’s superior pharmacodynamic properties, patients receiving carvedilol demonstrated a significantly lower hazard of hepatic decompensation (P < 0.001) and mortality (P = 0.031) compared with those treated with propranolol or nadolol. Although the study is subject to certain limitations, including its retrospective design, the reliance on thrombocytopenia as a surrogate marker for CSPH, and the inherent potential for diagnostic misclassification associated with ICD code–based identification, it nonetheless represents the largest investigation to date addressing this clinically important question through methodology reflective of contemporary clinical practice.
In conclusion, these findings align with evolving clinical guidelines and expert consensus recommendations,4,5 which increasingly advocate for the preferential use of carvedilol based not only on its superior efficacy in reducing hepatic venous pressure gradient and preventing variceal bleeding but also on its broader impact in mitigating hepatic decompensation and mortality among patients with compensated cirrhosis and CSPH. Collectively, this growing body of evidence paves the way for future prospective and controlled studies designed to refine the role of different NSBBs, with an emphasis on addressing clinically relevant, patient-centered outcomes.
—Ahmad Moussawi, MD, and Ranjeeta Bahirwani, MD
Transplant Hepatology, Baylor University Medical Center, Dallas, Texas, USA
Ranjeeta.Bahirwani@bswhealth.org
http://orcid.org/0000-0001-9828-7406
References
- 1.Frishman WH. Carvedilol. N Engl J Med. 1998;339(24):1759–1765. doi: 10.1056/NEJM199812103392407. [DOI] [PubMed] [Google Scholar]
- 2.Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393(10181):1597–1608. doi: 10.1016/S0140-6736(18)31875-0. [DOI] [PubMed] [Google Scholar]
- 3.Mullarkey MJ, Ogola GO, Asrani SK, Volk ML.. Carvedilol is associated with lower mortality than other nonselective beta-blockers in patients with cirrhosis. Proc (Bayl Univ Med Cent). 2025;38(4):412–418. doi: 10.1080/08998280.2025.2491220. [DOI] [Google Scholar]
- 4.De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi: 10.1016/j.jhep.2021.12.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kaplan DE, Ripoll C, Thiele M, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(5):1180–1211. doi: 10.1097/HEP.0000000000000647. [DOI] [PubMed] [Google Scholar]